Perianal Pediatric Crohn Disease Is Associated With a Distinct Phenotype and Greater Inflammatory Burden.

J Pediatr Gastroenterol Nutr

*Institute of Gastroenterology, Nutrition and Liver Disease, Schneider Children's Hospital, Petah Tikva, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel †Department of Radiology, Sheba Medical Center, Tel-Hashomer, Israel ‡Department of Diagnostic Imaging, Hospital for Sick Children §Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada ||Pediatric Radiology Unit, Shaare Zedek Medical Center, Jerusalem, Israel ¶Department of Radiology, Hospital Regional Universitario Carlos Haya, Malaga, Spain #Electroradiology Department, Faculty of Health Sciences, Collegium Medicum, Jagiellonian University, Cracow, Poland **Department of Radiology, University of Munich, Munich, Germany ††Department of Radiology, The Children's Hospital of Philadelphia, Philadelphia, PA ‡‡Department of Radiology, Cincinnati Children's Hospital, Cincinnati, OH §§Department of Radiology, Connecticut Children's Medical Center, Hartford, CT ||||Department of Radiology, Schneider Children's Hospital, Petah Tikva, Israel ¶¶Diagnostic Imaging Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel ##Division of Gastroenterology, Hospital for Sick Children, Toronto, Ontario, Canada ***Institute of Gastroenterology, Nutrition and Liver Disease, Shaare Zedek Medical Center, Jerusalem, Israel.

Published: September 2017

Objectives: Data on the outcomes of children with perianal Crohn disease (pCD) are limited, although its presence is often used for justifying early use of biologics. We aimed to assess whether pCD in children is associated with more severe outcomes as found in adults.

Methods: Data were extracted from the ImageKids database, a prospective, multicenter, longitudinal cohort study. The study enrolled 246 children at disease onset or thereafter. All patients underwent comprehensive clinical, endoscopic, and radiologic evaluation at enrollment; 98 children had repeat evaluation at 18 months.

Results: Of the 234 included patients (mean age 14.2 ± 2.4 years; 131 [56%] boys), 57 (24%) had perianal findings, whereas only 21 (9%) had fistulizing perianal disease. Children with pCD had reduced weight and height z scores compared with non-pCD patients (-0.9 vs -0.35, P = 0.03 and -0.68 vs -0.23, respectively; P = 0.04), higher weighted pediatric CD activity index (32 [interquartile range 16-50] vs 20 [8-37]; P = 0.004), lower serum albumin (3.6 ± 0.7 vs 4.5 ± 0.8, P = 0.016), and higher magnetic resonance enterography global inflammatory score (P = 0.04). Children with pCD had more rectal (57% vs 38%, P = 0.04), and jejunal involvement (31% vs 11% P = 0.003) and a higher prevalence of granulomas (64% vs 23%, P = 0.0001). Magnetic resonance enterography-based damage scores did not differ between groups. Patients with skin tags/fissures only, had similar clinical, endoscopic, and radiologic characteristics as patients with no perianal findings.

Conclusions: Pediatric patients with pCD with fistulizing disease have distinct phenotypic features and a predisposition to a greater inflammatory burden.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPG.0000000000001484DOI Listing

Publication Analysis

Top Keywords

crohn disease
8
greater inflammatory
8
inflammatory burden
8
clinical endoscopic
8
endoscopic radiologic
8
children pcd
8
magnetic resonance
8
children
6
patients
6
perianal
5

Similar Publications

The Incidence and Clinical Characteristics of COVID-19 in Children With IBD During the Omicron Wave: A Single-Center Experience in China.

Gastroenterol Res Pract

January 2025

Department of Gastroenterology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong Province, China.

The pandemic of coronavirus disease 2019 (COVID-19) had a major impact on the health of people worldwide, including the pediatric inflammatory bowel disease (PIBD) patients. As no study has investigated the susceptibility and disease course of COVID-19 in PIBD patients after the end of zero-COVID policy in China, we conducted a retrospective cross-sectional study in our center. A cross-sectional survey enrolling PIBD patients has been completed by online survey, phone, and face-to-face assessment.

View Article and Find Full Text PDF

Background: Drug-induced acute pancreatitis is a rare condition occurs at an incidence rate of 0.1-1.4% and represents a diagnostic challenge.

View Article and Find Full Text PDF

Objective: Patients with Crohn's disease (CD) commonly experience malnutrition. The Global Leadership Initiative on Malnutrition (GLIM) criteria, a novel approach to assessing malnutrition, has been validated in some diseases. However, there are limited studies in CD patients.

View Article and Find Full Text PDF

Background: The emergence of tumor necrosis factor inhibitors (anti-TNF) has considerably changed the management of inflammatory bowel disease (IBD) in patients who do not respond to traditional therapies. This study assesses the prevalence of anti-TNF drug levels (DLs) and antibodies (ATAbs) in patients with IBD in Saudi Arabia and explores their associations with IBD type and prior anti-TNF failure.

Methods: This cross-sectional study included patients aged 14-75 years diagnosed with Crohn's disease (CD) or ulcerative colitis (UC), treated with anti-TNF medications at King Fahad Medical City over January 2016 to December 2022.

View Article and Find Full Text PDF

Effectiveness and safety of biosimilars in pediatric inflammatory bowel diseases: an observational longitudinal study on the French National Health Data System.

World J Pediatr

January 2025

EPI-PHARE, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), 143-147 Boulevard Anatole France, 93285, Saint-Denis, France.

Background: Data on biosimilar use in pediatric inflammatory bowel diseases (IBD) are scarce compared to the status of studies in adults, resulting in limitations in its treatment. We compared effectiveness and safety of biosimilars versus originators in this population.

Methods: We used data from the French National Health Data System to identify children (less than 18 years old at treatment initiation) initiating treatment with a biosimilar or the originator infliximab or adalimumab for Crohn's disease (CD) or ulcerative colitis (UC), from first biosimilar launch (January 2015 and October 2018, respectively) to 31 December 2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!